Get the Stockscreener App
0.8024
5.61%
-0.0477
After Hours:
.80
-0.0024
-0.30%
Inflarx N V stock is traded at $0.8024, with a volume of 492.60K.
It is down -5.61% in the last 24 hours and down -52.80% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$0.8501
Open:
$0.826
24h Volume:
492.60K
Relative Volume:
1.09
Market Cap:
$53.87M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-0.9285
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
-56.63%
1M Performance:
-52.80%
6M Performance:
-67.38%
1Y Performance:
-43.89%
1-Day Range:
$0.80
$0.85
1-Week Range:
$0.7113
$1.90
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.8024 | 123.30M | 0 | -46.12M | -41.02M | -0.8642 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx (NASDAQ:IFRX) Price Target Cut to $3.00 by Analysts at Oppenheimer - Defense World
InflaRx stock rating cut, price target slashed to $2 by Raymond James - Investing.com Nigeria
InflaRx (IFRX) Maintains Outperform Rating, Price Target Adjusted | IFRX Stock News - GuruFocus
IFRX Price Target Cut as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating - marketscreener.com
Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13 - marketscreener.com
Guggenheim maintains $10 target on Inflarx despite study halt - Investing.com Australia
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Sto - GuruFocus
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
InflaRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks
Top Midday Decliners - marketscreener.com
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast - Benzinga
Guggenheim maintains $10 target on Inflarx despite study halt By Investing.com - Investing.com India
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
PG rating: Inflarx review declares phase III bomb - BioWorld MedTech
InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial - insights.citeline.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
InflaRx (IFRX) Halts Key Drug Trials, Refocuses Strategy - GuruFocus
InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum - TipRanks
InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell - marketscreener.com
InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha
InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus - GuruFocus
InflaRx to discontinue vilobelimab indication following IDMC recommendation - TipRanks
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire
InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp - Defense World
InflaRx to Participate in Upcoming Investor Conferences - The Manila Times
InflaRx Sets Ambitious Investor Conference Tour: Jefferies, Oppenheimer, and Leerink Partners Ahead - Stock Titan
Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX) - Defense World
Schonfeld Strategic Advisors LLC Sells 7,756 Shares of InflaRx (NASDAQ:IFRX) - Defense World
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Raymond James maintains Strong Buy on Inflarx stock, $13 target By Investing.com - Investing.com Nigeria
Raymond James maintains Strong Buy on Inflarx stock, $13 target - Investing.com
FY2025 EPS Estimates for InflaRx Raised by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for InflaRx Issued By Leerink Partnrs - Defense World
InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024) - Yahoo Finance
Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation - Nasdaq
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
InflaRx N.V. Reports Q1 2025 Financial Results - TipRanks
InflaRx reports Q1 EPS (EUR 0.13) vs (EUR 0.17) last year - TipRanks
InflaRx Reports Q1 2025 Financial Results with Reduced Losses - TipRanks
InflaRx (IFRX) Awaits Key Milestones in Drug Development | IFRX Stock News - GuruFocus
InflaRx N.V. Announces Progress in Toxicology Studies for INF904 and Upcoming Phase 3 Interim Analysis of Vilobelimab - Nasdaq
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
InflaRx NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews
Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World
InflaRx (NASDAQ:IFRX) Earns Overweight Rating from Analysts at Cantor Fitzgerald - Defense World
InflaRx (IFRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):